-
Nemvaleukin Alfa (Previously known as ALKS 4230) Drug Landscape Report 2024: An Interleukin-2 Receptor Agonist for the Treatment of Solid Tumors - Size, Forecasts, and Insights 2019-2032 - ResearchAndMarkets.com
18 Apr 2024 14:54 GMT
… in ovarian cancer.
Drug Summary
Nemvaleukin alfa (previously known as ALKS 4230 … ) is an interleukin-2 receptor agonist being developed by Alkermes … for the treatment of solid tumors, including head and neck cancer …
-
Fallopian Tube Cancer Market to witness growth by 2032, estimates DelveInsight
01 Apr 2024 12:30 GMT
… Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui …
Fallopian Tube Cancer Epidemiology
The Fallopian Tube Cancer epidemiology section provides … regulatory decisions.
Fallopian Tube Cancer Pipeline Development Activities
The …
-
Alkermes plc (NASDAQ:ALKS) Shares Purchased by Arizona State Retirement System
05 Feb 2024 11:55 GMT
… its holdings in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 2 … development for neurological disorders and cancer.
Featured Articles
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
Alkermes plc (NASDAQ:ALKS) Stock Holdings Boosted by Los Angeles Capital Management LLC
03 Feb 2024 10:35 GMT
… its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 120 … development for neurological disorders and cancer.
See Also
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
Raymond James & Associates Buys 6,510 Shares of Alkermes plc (NASDAQ:ALKS)
01 Feb 2024 09:36 GMT
… its holdings in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 32 … development for neurological disorders and cancer.
See Also
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
Alkermes plc Expected to Post FY2024 Earnings of $2.47 Per Share (NASDAQ:ALKS)
01 Feb 2024 09:42 GMT
Alkermes plc (NASDAQ:ALKS – Free Report) – Equities research analysts … by institutional investors.
Alkermes Company Profile
(Get Free Report)
Alkermes plc, a biopharmaceutical … disorders and cancer.
Read More
Receive News & Ratings for Alkermes Daily …
-
Alkermes plc (NASDAQ:ALKS) Short Interest Down 5.6% in January
01 Feb 2024 09:35 GMT
Alkermes plc (NASDAQ:ALKS – Get Free Report) saw a … Latest Analysis on Alkermes
About Alkermes
(Get Free Report)
Alkermes plc, a biopharmaceutical company … disorders and cancer.
Recommended Stories
Receive News & Ratings for Alkermes Daily …
-
California Public Employees Retirement System Raises Stake in Alkermes plc (NASDAQ:ALKS)
25 Jan 2024 11:44 GMT
… System boosted its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 13 … development for neurological disorders and cancer.
Further Reading
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …
-
EFG Asset Management North America Corp. Has $1.57 Million Holdings in Alkermes plc (NASDAQ:ALKS)
22 Jan 2024 16:22 GMT
… Corp. lessened its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 8 … Our Latest Report on Alkermes
Alkermes Profile
(Free Report)
Alkermes plc, a biopharmaceutical company … disorders and cancer.
Read More
Receive News & Ratings for Alkermes Daily …
-
TD Asset Management Inc Buys Shares of 56,000 Alkermes plc (NASDAQ:ALKS)
21 Jan 2024 11:31 GMT
… bought a new stake in Alkermes plc (NASDAQ:ALKS – Free Report) during the … development for neurological disorders and cancer.
See Also
Want to see … filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News …